ClinicalTrials.gg
Status unknownNCT03189160Updated Dec 12, 2017

A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome

A Phase 2 interventional study of PEG-rhGH low dose and PEG-rhGH high dose in Turner Syndrome, sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Status unknown at 9 sites in China. Open to female participants aged 2 Years to 18 Years. Per ClinicalTrials.gov, last updated 2017-12-12.

Sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Jun 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
2 Years to 18 Years
Sex
Female
01

Study summary

This study aims to explore the optimal dose of pegylated recombinant human growth hormone (PEG-rhGH) injection to treat children of Turner syndrome (TS), preliminarily evaluate its safety and efficacy and provide scientific and reliable evidence for the medication dosage in Phase 3 clinical trial.

02

Conditions studied

  • Turner Syndrome

Browse trials for

03

In context

Turner Syndrome

125 studies on the registry are indexed under Turner Syndrome; 33 are open to participants now.

This study's planned enrollment of 180 is above the median of 67 across 52 interventional studies indexed under Turner Syndrome.

Browse Turner Syndrome studies →

Lead sponsor

Changchun GeneScience Pharmaceutical Co., Ltd. is the lead sponsor of 112 studies on the registry; 47 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 18 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • Bone age \<12 years
  • Karyotype: 45, X; 45, X / 46, XXqi; 45, X / 46, XXr; 45, X / 46, XX; 46, XXqi; 46, XXpi; 45, X / 47, XXX; 46, XXp-; 45, X / 46, XXp-; 46, XXq-; 45X / 46, XXq-; 45, X / 46, XX / 47, XXX, etc. (count 50 or more cells);
  • Facial appearance and abnormalities: Patients with at least one of the following signs, which include but are not limited to facial pigmented nevus, short neck, webbed neck, low posterior hairline, low-set ears, micrognathia, high-voulted arch, shield-like chest, cubitus valgus, genu valgum, short 4th and 5th metacarpals, nail dysplasia, scoliosis, ptosis and strabismus, cardiovascular abnormalities (such as aortic stenosis, bicuspid aortic valve and hypertension), reproductive abnormalities (such as primary gonadal dysfunction), renal abnormalities, thyroid hypofunction, middle ear lesion, etc.
  • Short stature: height below -2.5SD of the mean height of the same age and gender.
  • Pre-pubertal (Tanner Stage I ) patients
  • No history of growth hormone treatment
  • The subject and his/her guardian sign the (if the subject is incapable to sign the informed consent, his/her legal guardian shall sign the name of the subject instead)

Exclusion criteria

Exclusion Criteria:

  • Subjects with abnormal liver and kidney functions ( > value; Cr > upper limit of normal value)
  • Subjects positive for , HbsAg or HbeAg in Hepatitis B virus tests;
  • Subjects with highly allergic constitution or allergy to proteins or product or its
  • Subjects with systemic chronic disease and immune deficiency
  • Patients diagnosed with tumor
  • For patients whose tumor markers exceeding normal range in combination with other information, considering as potential high risks of tumor, they may be excluded from the treatment.
  • Patients with mental disease
  • Subjects with impaired glucose regulation (IGR) (including impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) ) or diabetes
  • Subjects who took part in other clinical trials within 3 months
  • Subjects who received medicines which may interfere GH secretion or GH function, or other hormones within 3 months (such as sex , glucocorticoids, etc.)
  • Other conditions which are unsuitable for this study in the opinion of the investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    PEG-rhGH low dose

    PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.

    Biological: PEG-rhGH low dose · Biological: PEG-rhGH high dose · Other: Non-treatment control group

  • Experimental
    PEG-rhGH high dose

    PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.

    Biological: PEG-rhGH low dose · Biological: PEG-rhGH high dose · Other: Non-treatment control group

  • No intervention
    Non-treatment control group

Interventions

  • BiologicalPEG-rhGH low dose

    PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.

    Also known as: Polyethylene Glycol Recombinant Human Somatropin Injection

  • BiologicalPEG-rhGH high dose

    PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.

    Also known as: Polyethylene Glycol Recombinant Human Somatropin Injection

  • OtherNon-treatment control group
06

What researchers measure

Primary outcomes

  1. Change of height standard deviation score before and after treatment (ΔHT SDS)

    The change of height standard deviation score of chronological age before and after treatment

    Time frame: 52 weeks

Secondary outcomes

  1. Height Velocity

    Annual growth rate at the end of treatment

    Time frame: 52 weeks

  2. ΔBA/ΔCA

    Bone maturation (changes of bone age/ chang of chronological age)

    Time frame: 52 weeks

  3. IGF-1(Insulin-like growth factor 1) SDS

    Time frame: 52 weeks

07

Study locations

9 of 9 sites recruiting
  • The First Affiliated Hospital with Nanjing Medical University
    Nanjing, Jiangsu, China
    Recruiting
    • Yuhua Hu · Contact
  • Affiliated Hospital of Jiangnan University
    Wuxi, Jiangsu, China
    Recruiting
    • Zhuangjian Xu · Contact
  • Jiangxi Provincial Children's Hospital
    Nanchang, Jiangxi, China
    Recruiting
    • Yu Yang · Contact
  • First Hospital of Jilin University
    Changchun, Jilin, China
    Recruiting
    • Hongwei Du · Contact
  • The Children's Hospital of Zhejiang University School of Medicine
    Hangzhou, Zhejiang, China
    Recruiting
    • Junfeng Fu · Contact
  • Beijing Children's Hospital,Capital Medical University
    Beijing, China
    Recruiting
    • Chunxiu Gong, PhD · Contact
  • Children's Hospital of Fudan University
    Shanghai, China
    Recruiting
    • Feihong Luo · Contact
  • Shanghai Children's Hospital
    Shanghai, China
    Recruiting
    • Pin Li · Contact
  • Xinhua Hospital of Shanghai Jiao Tong University School of Medicine
    Shanghai, China
    Recruiting
    • Jun Ye · Contact
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016 and a primary completion of Mar 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2017
First posted
Jun 16, 2017
Start
Mar 2016
Primary completionEst.
Mar 2018
Last update
Dec 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03189160
Collaborators
Beijing Children's Hospital, The First Affiliated Hospital with Nanjing Medical University, Shanghai Children's Hospital, Children's Hospital of Fudan University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, The First Hospital of Jilin University, Jiangxi Province Children's Hospital, Affiliated Hospital of Jiangnan University, The Children's Hospital of Zhejiang University School of Medicine
Responsible party
Sponsor
First posted
Jun 16, 2017
Start date
Mar 2016
Primary completion
Mar 2018 (estimated)
Last update
Dec 12, 2017

Study contacts

Xiaohua Feng
Contact
fengxiaohua@gensci-china.com
0431-85170552
Chunxiu Gong, PhD
principal investigator · Beijing Children's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion